Repositioning Candidate Details
| Candidate ID: | R1095 |
| Source ID: | DB06777 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Chenodeoxycholic acid |
| Synonyms: | 3alpha,7alpha-Dihydroxy-5beta-cholanic acid; 7α-hydroxylithocholic acid; Anthropodeoxycholic acid; Anthropodesoxycholic acid; CDCA; Chenic acid; Chenocholic acid; Chenodeoxycholate; Chenodeoxycholic acid; Chenodesoxycholic acid; Chenodiol; Gallodesoxycholic acid |
| Molecular Formula: | C24H40O4 |
| SMILES: | [H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O |
| Structure: |
|
| DrugBank Description: | Chenodeoxycholic acid (or Chenodiol) is an epimer of ursodeoxycholic acid (DB01586). Chenodeoxycholic acid is a bile acid naturally found in the body. It works by dissolving the cholesterol that makes gallstones and inhibiting production of cholesterol in the liver and absorption in the intestines, which helps to decrease the formation of gallstones. It can also reduce the amount of other bile acids that can be harmful to liver cells when levels are elevated. |
| CAS Number: | 474-25-9 |
| Molecular Weight: | 392.572 |
| DrugBank Indication: | Chenodiol is indicated for patients with radiolucent stones in well-opacifying gallbladders, in whom selective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age. Chenodiol will not dissolve calcified (radiopaque) or radiolucent bile pigment stones. |
| DrugBank Pharmacology: | It acts by reducing levels of cholesterol in the bile, helping gallstones that are made predominantly of cholesterol to dissolve. Chenodeoxycholic acid is ineffective with stones of a high calcium or bile acid content. |
| DrugBank MoA: | Chenodiol suppresses hepatic synthesis of both cholesterol and cholic acid, gradually replacing the latter and its metabolite, deoxycholic acid in an expanded bile acid pool. These actions contribute to biliary cholesterol desaturation and gradual dissolution of radiolucent cholesterol gallstones in the presence of a gall-bladder visualized by oral cholecystography. Bile acids may also bind the the bile acid receptor (FXR) which regulates the synthesis and transport of bile acids. |
| Targets: | Bile acid receptor other; Nuclear receptor subfamily 1 group I member 2; G-protein coupled bile acid receptor 1; Aldo-keto reductase family 1 member C2 substrate |
| Inclusion Criteria: | Target associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|